SCHEMBL24348497

SCHEMBL24348497

Cc1nc(COC(C)C(=O)N(C)C)sc1-c1csc(-c2cc(F)c(O)c(F)c2F)n1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BPGM P07738 5/20 0.66
▸ PIK3CD O00329 2/20 0.31
▸ PIK3CA P42336 2/20 0.31
▸ PIK3CG P48736 2/20 0.31
▸ PIK3CB P42338 1/20 0.31
▸ MEN1 O00255 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ LMNA P02545 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ HPGD P15428 1/20 0.31
▸ ALOX12 P18054 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24348057 0.86 BPGM (0.69) BPGMPIK3CDPIK3CAMEN1NPC1
SCHEMBL24348048 0.86 BPGM (0.49) BPGM
SCHEMBL24349243 0.84 BPGM (0.67) BPGMPIK3CDPIK3CAMEN1NPC1
SCHEMBL24348485 0.82 BPGM (0.69) BPGMPIK3CDPIK3CAPIK3CGMEN1
SCHEMBL24348036 0.80 BPGM (0.61) BPGMPIK3CDPIK3CAPIK3CGPIK3CB
SCHEMBL24348039 0.80 BPGM (0.71) BPGMPIK3CDPIK3CAPIK3CGMEN1
SCHEMBL24347958 0.79 BPGM (1.00) BPGMPIK3CDPIK3CAPIK3CGMEN1
SCHEMBL24348548 0.79 BPGM (0.77) BPGMPIK3CDPIK3CAPIK3CGMEN1
SCHEMBL24348501 0.78 BPGM (0.63) BPGMPIK3CDPIK3CAPIK3CGPIK3CB
SCHEMBL24348996 0.76 BPGM (0.64) BPGMMEN1NPC1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION 2023-11-02 — — US disclosed
WO-2022056449-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE GENZYME CORPORATION (US) 2022-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348454-A1 COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE BPGM, PGAM1, HBG1 BPGM 1/4885PIK3CD 1201/4885PIK3CA 568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback